<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20180110038302N8</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-12-14</date_registration>
      <primary_sponsor>Alborz University of Medical Sciences</primary_sponsor>
      <public_title>The effect of ginger suppository on the treatment of headache and chills after spinal anesthesia</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of ginger suppository and placebo on headache and chills after spinal anesthesia in cesarean section patients</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-01-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>100</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/56984</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: First, a list of eligible people is prepared in Excel software. Then, the subjects are divided into two groups of intervention and control by block randomization method with 4 equal blocks, which is done with websites( www.randomization.com can do block randomization more easily). In this method, the size of all blocks is equal. In this study, with a 100 sample size, the number of blocks is 4 and the size of each block is 25. Two blocks (50 people) belong to an intervention group and two blocks (50 people) belong to the control group, Blinding description: This study is single blind. The patient does not know which drug is the main drug and which is the placebo. The intervention group is given the main drug and the control group is given the placebo. The color, smell, weight, and other characteristics of the placebo are as the same as the main drug.</study_design>
      <phase>3</phase>
      <hc_freetext>Headache and chills after spinal anesthesia in women with cesarean section.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: The main drug (ginger suppository) is given to the patient after cesarean section. A ginger suppository is given every 8 hours for the first 24 hours after cesarean section. The manufacturer of medicine is the Faculty of Pharmacy of Alborz University. This suppository is not available in the market. Intervention 2: Control group: "Placebo in the form of a ginger suppository" is given to the patient in the form of ginger suppository after cesarean section. A placebo is given as a ginger suppository every 8 hours for the first 24 hours after cesarean section. The manufacturer of medicine in the Faculty of Pharmacy of Alborz University. This suppository is not available in the market.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All data is potentially shareable after unidentified individuals.

When:
"Access period starts 6 months after the results are published".

To whom:
Our data will be available to researchers working in academic and scientific institutions, or to people who are also involved in the industry.

Conditions:
Receive documentation from them based on the academic degree or employment in the industry.

Where to obtain:
Call this phone number: 00989124195752

How to obtain:
After the accuracy of the submitted documents, the data will be sent within a maximum of 2 weeks.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mansoureh Yazdkhasti</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>NO.14, Medicine school, Ooge Blvd, West BooAli Highway</address>
        <city>Karaj</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3149969415</zip>
        <telephone>+98 26 3264 2815</telephone>
        <email>Mansoyazd@yahoo.com</email>
        <affiliation>Alborz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mansoureh Yazdkhasti</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>NO.14, Medicine school, Ooge Blvd, West BooAli Highway</address>
        <city>Karaj</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3149969415</zip>
        <telephone>+98 26 3264 2815</telephone>
        <email>Mansoyazd@yahoo.com</email>
        <affiliation>Alborz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Women aged 15 to 49 years
Full-term pregnancy (37 full weeks of pregnancy)
Singleton pregnancy
Anesthesia class ASA I, ASA II(American Society of Anesthesiologists Physical Status Classification  )
Non-emergency cesarean section
Headache in the first 72 hours</inclusion_criteria>
      <agemin>15 years</agemin>
      <agemax>49 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>The cesarean section lasted more than an hour
Attempted more than twice for spinal anesthesia
Sensitivity to ginger
Taking psychotropic drugs or narcotics
Alcoholism</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>O74.5</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Spinal and epidural anesthesia-induced headache during labor and delivery</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: The main drug (ginger suppository) is given to the patient after cesarean section. A ginger suppository is given every 8 hours for the first 24 hours after cesarean section. The manufacturer of medicine is the Faculty of Pharmacy of Alborz University. This suppository is not available in the market.</i_keyword>
      <i_keyword>Control group: "Placebo in the form of a ginger suppository" is given to the patient in the form of ginger suppository after cesarean section. A placebo is given as a ginger suppository every 8 hours for the first 24 hours after cesarean section. The manufacturer of medicine in the Faculty of Pharmacy of Alborz University. This suppository is not available in the market.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Headache score in Visual scale of pain. Timepoint: In both groups, pain intensity will be measured at 6-time points (0.5, 1, 1.5, 3, 6, 12) hours after the operation. Method of measurement: visual scale of pain questionnaire.</prim_outcome>
      <prim_outcome>Shivering score in Crossley and Mahajan questionnaire. Timepoint: The severity of chills, from 20 to 95 minutes after cesarean section every 15 minutes. Method of measurement: Crossley and Mahajan questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Alborz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-02-17</approval_date>
        <contact_name>Ethics committee of Alborz University of Medical Sciences</contact_name>
        <contact_address>NO.14, Medicine school, Ooge Blvd, West BooAli Highway Karaj Alborz Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
